Treatment outcome for flexible dosing buprenorphine maintenance treatment

American Journal of Drug and Alcohol Abuse

Volumn 38, Issue 2, 2012, Pages 155-160

  Fareed, Ayman ^a   Vayalapalli, Sreedevi ^a   Casarella, Jennifer ^a   Drexler, Karen ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Dosing; Flexible; Outcome

Indexed keywords

BUPRENORPHINE; COCAINE; OPIATE;

ADULT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG ABUSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; TREATMENT OUTCOME;

ADULT; BUPRENORPHINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84857552641     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.643988     Document Type: Article

References (26)

1. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274:361-372.
2. Cowan A, Ph D. Buprenorphine: The basic pharmacology revisited. J Addict Med 2007; 1(2):68-72.
3. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-580. (Pubitemid 24192243)
4. Liguori A,Morse WH, Bergman J. Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 1996; 277:462-472. (Pubitemid 27169093)
5. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96:627-632.
6. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40:17-25.
7. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004; 13(1):S42-S66. (Pubitemid 38585690)
8. Caldiero R, Parran T, Jr, Adelman C, Piche B. Inpatient initiation of buprenorphine maintenance vs. detoxification: Can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict 2006; 15:1-7. (Pubitemid 43207183)
9. White J, Bell J, Saunders J, Williamson P, Makowska M, Farquharson A, Beebe K. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009; 103:37-43.
10. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4):441-452. (Pubitemid 36458126)
11. Greenwald MK, Johanson CE, Schuster CR. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 1999; 56(3):191-203. (Pubitemid 29401888)
12. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53(5): 401-407. (Pubitemid 26149228)
13. Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998; 4(1): 3-7. (Pubitemid 28478987)
14. Comer S, Collins E, Fischman MW. Buprenorphine sublingual tablets: Effects on IV heroin self-administration by humans. Psychopharmacology 2001; 154:28-37. (Pubitemid 32186512)
15. Greenwald M, Schuh K, Hopper J, Schuster C, Johanson C. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 2002; 160:344-352. (Pubitemid 34253276)
16. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 2003; 361(9358):662-668. (Pubitemid 36246548)
17. LingW, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998; 93:475-486. (Pubitemid 28188067)
18. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 49(10): 949-958. (Pubitemid 37064768)
19. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and METH for opioid dependence. N Engl J Med 2000; 343:1290-1297.
20. Kakko J, Grönbladh L, Svanborg KD, von Wachenfeldt J, Rück C, Rawlings B, Nilsson LH, Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. Am J Psychiatry 2007; 164(5): 797-803. (Pubitemid 46808535)
21. Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: Secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend 2010; 107(2-3):253-256.
22. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006; 20(6):806-814. (Pubitemid 44622745)
23. Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, Muenz LR, Thase ME, Weiss RD, Gastfriend DR, Woody GE, Barber JP, Butler SF, Daley D, Salloum I, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck AT. Psychosocial treatments for cocaine dependence: National institute on drug abuse collaborative cocaine treatment study. Arch Gen Psychiatry 1999; 56:493-502. (Pubitemid 29304640)
24. Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003; 70:315-325. (Pubitemid 36577343)
25. Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005; 162:340-349. (Pubitemid 40216216)
26. Simpson DD, Joe GW, Fletcher BW, Hubbard RL, Anglin MD. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56:507-514. (Pubitemid 29304643)